Cite
HARVARD Citation
Smithy, J. et al. (2017). Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Journal for immunotherapy of cancer. 5 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Smithy, J. et al. (2017). Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Journal for immunotherapy of cancer. 5 (1), p. . [Online].